1. Immunogenicity of biotechnology-derived therapeutics: assessment and interpretation of nonclinical safety studies;Ponce;Regul Toxicol Pharmacol,2009
2. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans;Bugelski;Curr Opin Mol Ther,2004
3. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins;European Medicines Agency (EMEA),2007
4. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH): S6 (R1) preclinical safety evaluation of biotechnology-derived pharmaceuticals, 2011.
5. Immunology;Male,2013